Literature DB >> 1322960

Mechanisms of bovine herpesvirus type 1 neutralization by monoclonal antibodies to glycoproteins gI, gIII and gIV.

J Dubuisson1, B A Israel, G J Letchworth.   

Abstract

We examined a panel of monoclonal antibodies (MAbs) against bovine herpesvirus type 1 (BHV-1) glycoproteins gI, gIII and gIV for inhibition of virus attachment and interference with subsequent steps of infection. Attachment of radiolabelled virions was partially prevented by 600 to 700 micrograms/ml of IgM antibodies against gI and gIII and one IgG2A antibody against gIV, but not by the majority of MAbs against any of the three viral glycoproteins. Productive infection following attachment was prevented by lower concentrations of MAbs 5106 and 4807 against gI and by 0.7 to 5.5 micrograms/ml of all five MAbs against gIV. MAbs against gIV had almost the same activity whether added before or after BHV-1 was incubated with cells, suggesting that their principal activity is to prevent the penetration of virus through the cell membrane. The ability of polyethylene glycol to overcome neutralization by one anti-gIV MAb supported this concept, but an attempt to confirm this by direct electron microscopy failed. A bovine monospecific antiserum against gIV had approximately 10-fold more neutralizing activity against BHV-1 than did antisera against gI or gIII. Complement increased the activity of anti-gI and anti-gIII MAbs by 10- to 100-fold, but had little or no effect on neutralization by anti-gIV MAbs. Some antibodies against gI and gIV inhibited the enlargement of plaques in cell cultures. Taken together, these data suggest that MAbs against gIV are the principal agents of BHV-1 neutralization, and that these antibodies can be fully effective in areas such as the ocular and respiratory mucosae, from which complement is absent at the time of primary exposure to infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322960     DOI: 10.1099/0022-1317-73-8-2031

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Use of epitope mapping to identify a PCR template for protein amplification and detection by enzyme-linked immunosorbent assay of bovine herpesvirus type 1 glycoprotein D.

Authors:  Tomy Joseph; Japhet Lyaku; Robert A Fredrickson; Arnost Cepica; Frederick S B Kibenge
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Production and characterization of bovine herpesvirus 1 glycoprotein B ectodomain derivatives in an hsp70A gene promoter-based expression system.

Authors:  Y Li; S Van Drunen Littel-Van den Hurk; X Liang; L A Babiuk
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Glycoprotein Bb, the N-terminal subunit of bovine herpesvirus 1 gB, can bind to heparan sulfate on the surfaces of Madin-Darby bovine kidney cells.

Authors:  Y Li; X Liang; S van Drunen Littel-van den Hurk; S Attah-Poku; L A Babiuk
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Characterization of cell-binding properties of bovine herpesvirus 1 glycoproteins B, C, and D: identification of a dual cell-binding function of gB.

Authors:  Y Li; S van Drunen Littel-van den Hurk; L A Babiuk; X Liang
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

5.  Identification of 108K, 93K, and 42K glycoproteins of bovine herpesvirus-1 by monoclonal antibodies.

Authors:  E Baranowski; J Dubuisson; P P Pastoret; E Thiry
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1.

Authors:  Sunil K Khattar; Peter L Collins; Siba K Samal
Journal:  Vaccine       Date:  2010-02-26       Impact factor: 3.641

7.  Induction of humoral responses to BHV-1 glycoprotein D expressed by HSV-1 amplicon vectors.

Authors:  Andrea Maria Blanc; Mabel Beatriz Berois; Lorena Magalí Tomé; Alberto L Epstein; Juan Ramón Arbiza
Journal:  J Vet Sci       Date:  2012-03       Impact factor: 1.672

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.